Ser727
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser727  -  STAT3 (human)

Site Information
NtIDLPMsPRTLDSL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448191

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 25 ) , [32P] ATP in vitro ( 75 ) , [32P] bio-synthetic labeling ( 179 ) , electrophoretic mobility shift ( 166 , 181 ) , flow cytometry ( 77 , 173 ) , immunoassay ( 44 ) , immunoprecipitation ( 6 , 9 , 10 , 15 , 25 , 45 , 77 , 104 , 142 , 188 , 191 , 192 , 193 ) , mass spectrometry ( 7 , 11 , 12 , 14 , 15 , 19 , 20 , 21 , 22 , 23 , 24 , 27 , 28 , 30 , 31 , 32 , 33 , 35 , 36 , 38 , 42 , 46 , 47 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 103 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 116 , 119 , 122 , 123 , 124 , 129 , 130 , 133 , 134 , 136 , 137 , 138 , 141 ) , modification-specific antibody ( 15 ) , mutation of modification site ( 3 , 6 , 9 , 10 , 15 , 18 , 22 , 125 , 128 , 139 , 144 , 146 , 147 , 150 , 159 , 161 , 165 , 174 , 175 , 178 , 179 , 181 , 183 , 188 , 194 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 9 , 10 , 13 , 15 , 16 , 18 , 22 , 25 , 26 , 39 , 40 , 41 , 43 , 44 , 45 , 48 , 49 , 75 , 76 , 77 , 102 , 104 , 115 , 117 , 118 , 120 , 121 , 126 , 127 , 128 , 131 , 135 , 139 , 140 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 180 , 181 , 182 , 184 , 185 , 187 , 189 , 190 , 191 , 192 , 193 , 195 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 6 , 9 , 10 , 13 , 15 , 16 , 18 , 22 , 25 , 26 , 39 , 40 , 41 , 43 , 45 , 48 , 49 , 75 , 76 , 77 , 102 , 104 , 115 , 117 , 118 , 120 , 121 , 126 , 127 , 128 , 131 , 135 , 139 , 140 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 155 , 156 , 157 , 160 , 161 , 163 , 164 , 165 , 167 , 168 , 171 , 172 , 173 , 174 , 176 , 185 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 195 )
Disease tissue studied:
brain cancer ( 49 , 102 , 118 , 190 ) , glioblastoma ( 49 , 102 ) , glioblastoma multiforme ( 49 , 102 ) , glioma ( 49 , 102 ) , medulloblastoma ( 118 ) , breast cancer ( 3 , 9 , 13 , 20 , 21 , 32 , 33 , 76 , 102 , 104 , 127 , 163 ) , breast ductal carcinoma ( 20 ) , HER2 positive breast cancer ( 7 ) , luminal A breast cancer ( 7 ) , luminal B breast cancer ( 7 ) , breast cancer, surrounding tissue ( 7 ) , breast cancer, triple negative ( 7 , 9 , 20 ) , cervical cancer ( 119 ) , cervical adenocarcinoma ( 119 ) , colorectal cancer ( 15 , 77 , 127 , 157 ) , colorectal carcinoma ( 15 , 77 , 127 , 157 ) , gastric cancer ( 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 72 , 78 , 79 , 80 , 82 , 83 , 84 , 88 , 89 , 90 , 93 , 94 , 97 , 99 , 103 , 106 , 107 , 108 , 109 ) , gastric carcinoma ( 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 72 , 78 , 79 , 80 , 82 , 83 , 84 , 88 , 89 , 90 , 93 , 94 , 97 , 99 , 103 , 106 , 107 , 108 , 109 ) , leukemia ( 38 , 48 , 114 , 133 , 154 , 161 , 165 , 173 , 176 , 185 , 187 ) , acute lymphocytic leukemia ( 48 ) , acute myelogenous leukemia ( 38 , 173 , 176 , 187 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 31 , 161 , 165 ) , acute megakaryoblastic leukemia (M7) ( 31 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 31 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 31 ) , acute myeloblastic leukemia, without maturation (M1) ( 31 ) , chronic lymphocytic leukemia ( 48 , 154 ) , chronic myelogenous leukemia ( 114 , 133 ) , liver cancer ( 120 , 135 , 139 , 140 , 151 , 172 , 174 , 187 , 189 ) , hepatocellular carcinoma ( 18 ) , lung cancer ( 33 , 45 , 68 , 69 , 70 , 71 , 73 , 74 , 81 , 85 , 86 , 87 , 91 , 92 , 95 , 96 , 98 , 100 , 102 , 110 ) , non-small cell lung cancer ( 33 , 45 , 68 , 69 , 70 , 71 , 73 , 74 , 81 , 85 , 86 , 87 , 91 , 92 , 95 , 96 , 98 , 100 , 102 , 110 ) , non-small cell lung adenocarcinoma ( 45 , 70 , 73 , 74 , 81 , 86 , 91 , 92 , 95 , 96 , 98 , 100 , 110 ) , non-small cell squamous cell lung carcinoma ( 70 , 73 , 74 , 81 , 86 , 110 ) , lymphoma ( 6 , 48 , 177 , 191 ) , anaplastic large cell lymphoma ( 177 ) , B cell lymphoma ( 31 ) , Burkitt's lymphoma ( 48 , 191 ) , non-Hodgkin's lymphoma ( 31 ) , nasopharyngeal carcinoma ( 25 ) , neuroblastoma ( 151 , 190 ) , ovarian cancer ( 20 , 121 ) , pancreatic cancer ( 40 , 102 , 155 ) , pancreatic carcinoma ( 40 , 102 , 155 ) , pancreatic ductal adenocarcinoma ( 24 , 40 ) , multiple myeloma ( 31 , 41 ) , plasmacytoma ( 172 ) , prostate cancer ( 2 , 9 , 102 , 126 , 127 , 128 , 144 , 145 , 195 ) , melanoma skin cancer ( 14 , 102 , 167 ) , cancer, squamous cell carcinoma ( 142 ) , thyroid cancer ( 147 , 148 ) , medullary thyroid carcinoma ( 147 ) , colonic inflamation ( 12 ) , neurofibromatosis type 1 ( 115 )
Relevant cell line - cell type - tissue:
'brain, cerebellum' ( 118 ) , 'muscle, smooth' ( 125 ) , 'pancreatic, ductal'-pancreas ( 24 ) , 'stem, prostate cancer' ( 5 ) , 1205Lu (melanocyte) ( 167 ) , 293 (epithelial) ( 1 , 75 , 104 , 123 , 144 , 147 , 149 , 161 , 165 , 190 ) , 293E (epithelial) ( 174 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 178 , 181 ) , 3T3 (fibroblast) ( 147 , 163 , 192 ) , 6-10B (epithelial) ( 25 ) , 786-O (renal) [VHL (human), transfection] ( 11 ) , 786-O (renal) ( 11 ) , A2780 (ovarian) ( 121 ) , A431 (epithelial) ( 162 ) , A549 (pulmonary) ( 27 ) , AML-193 (monocyte) ( 31 ) , Aspc1 (pancreatic) ( 40 ) , B lymphocyte ( 48 ) , B lymphocyte-blood ( 154 ) , BaF3 ('B lymphocyte, precursor') ( 176 ) , BJAB (B lymphocyte) ( 48 ) , breast ( 7 , 20 ) , BT-20 (breast cell) ( 33 ) , BT-549 (breast cell) ( 33 ) , Calu 6 (pulmonary) ( 33 ) , Chang liver (cervical) ( 134 ) , CLL23LB4 (B lymphocyte) ( 43 ) , CMK (megakaryoblast) ( 31 ) , COS (fibroblast) ( 171 , 175 , 178 , 192 , 194 ) , CTS (myeloid) ( 31 ) , Daoy ( 118 ) , DHL (T lymphocyte) ( 177 ) , DLD1 (intestinal) ( 15 ) , DOHH2 ('B lymphocyte, precursor') ( 31 ) , DU 145 (prostate cell) ( 2 , 102 , 127 , 145 ) , EC (endothelial) ( 22 ) , endothelial-aorta ( 35 , 184 ) , epidermal ( 75 ) , epithelial-prostate ( 128 ) , FEMX (melanocyte) ( 167 ) , Focus (hepatic) ( 18 ) , Fr 3T3 (fibroblast) ( 188 ) , GM03317 ( 170 ) , H2009 (pulmonary) ( 33 ) , H2077 (pulmonary) ( 33 ) , H2887 (pulmonary) ( 33 ) , H322M (pulmonary) ( 33 ) , H4IIe (hepatic) ( 174 ) , HCC1359 (pulmonary) ( 33 ) , HCC1937 (breast cell) ( 33 ) , HCC2279 (pulmonary) ( 33 ) , HCC366 (pulmonary) ( 33 ) , HCC4006 (pulmonary) ( 33 ) , HCC78 (pulmonary) ( 33 ) , HCC827 (pulmonary) ( 33 , 45 ) , HCT116 (intestinal) ( 77 , 127 ) , HEK293T (epithelial) ( 12 , 15 , 142 , 181 ) , HEL (erythroid) ( 31 , 152 , 161 , 165 ) , HeLa (cervical) ( 10 , 19 , 30 , 47 , 50 , 75 , 111 , 112 , 127 , 130 , 142 , 159 , 162 , 179 ) , HeLa S3 (cervical) ( 119 , 129 ) , Hep 3B2.1-7 (hepatic) ( 135 ) , HEp-3 ( 142 ) , hepatocyte ( 120 ) , hepatocyte-liver ( 164 ) , HepG2 (hepatic) ( 120 , 139 , 140 , 151 , 172 , 175 , 180 , 181 , 183 , 187 , 189 ) , HMEC (endothelial) ( 13 , 131 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 21 ) , HMLER ('stem, breast cancer') ( 21 ) , HOP62 (pulmonary) ( 33 ) , HT-29 (intestinal) ( 77 , 157 ) , HT1080 (fibroblast) ( 179 ) , HTR8/SVneo (trophoblast) ( 4 ) , HUES-7 ('stem, embryonic') ( 122 ) , HUES-9 ('stem, embryonic') ( 46 ) , HUVEC (endothelial) ( 6 , 16 , 26 ) , IMR32 (neural crest) ( 151 ) , Jurkat (T lymphocyte) ( 28 , 42 , 101 , 105 , 113 , 136 , 137 , 138 , 141 , 160 ) , K562 (erythroid) ( 30 , 114 , 133 ) , Karpas-299 (T lymphocyte) ( 177 ) , Kasumi-1 (myeloid) ( 31 ) , KG-1 (myeloid) ( 31 , 38 ) , Kit225 (T lymphocyte) ( 193 ) , KP-4 (pancreatic) ( 40 ) , LCLC-103H (pulmonary) ( 33 ) , leukocyte-blood ( 116 ) , liver ( 23 ) , LNCaP (prostate cell) ( 127 , 128 , 144 , 195 ) , LOU-NH91 (squamous) ( 33 ) , lymph node ( 12 ) , M-07e (myeloid) ( 185 ) , M059K (glial) ( 102 ) , macrophage-blood ( 166 ) , MCF-10A (breast cell) ( 127 , 163 ) , MCF-7 (breast cell) ( 13 , 33 , 102 , 104 ) , MDA-MB-231 (breast cell) ( 3 , 9 , 33 , 102 ) , MDA-MB-453 (breast cell) ( 127 ) , MDA-MB-468 (breast cell) ( 33 , 127 , 163 ) , MDCK (epithelial) ( 146 ) , MEF (fibroblast) ( 3 , 6 ) , MEF (fibroblast) [IGF1R (mouse)] ( 182 ) , MIA PaCa-2 (pancreatic) ( 40 , 153 ) , MKN-45 (gastric) ( 36 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 72 , 78 , 79 , 80 , 82 , 83 , 84 , 88 , 89 , 90 , 93 , 94 , 97 , 99 , 103 , 106 , 107 , 108 , 109 ) , monocyte ( 143 , 150 , 168 ) , monocyte-blood ( 39 ) , mononuclear ( 156 ) , MSTO-211H (mesothelial) ( 170 ) , MV4-11 (macrophage) ( 31 ) , myeloid-blood ( 187 ) , myocyte-heart ( 16 ) , NALM6 (B lymphocyte) ( 48 ) , NBFL ( 190 ) , NCI-H1395 (pulmonary) ( 33 ) , NCI-H1568 (pulmonary) ( 33 ) , NCI-H157 (pulmonary) ( 33 ) , NCI-H1648 (pulmonary) ( 33 ) , NCI-H1650 (pulmonary) ( 102 ) , NCI-H1666 (pulmonary) ( 33 ) , NCI-H1703 (squamous) ( 36 , 70 , 73 , 74 , 81 , 86 , 110 ) , NCI-H2030 (pulmonary) ( 33 ) , NCI-H2172 (pulmonary) ( 33 ) , NCI-H322 (pulmonary) ( 33 ) , NCI-H3255 (pulmonary) ( 36 , 68 , 69 , 71 , 85 , 87 ) , NCI-H441 (pulmonary) ( 91 , 92 , 95 , 96 , 98 , 100 ) , NCI-H460 (pulmonary) ( 33 ) , NCI-H520 (squamous) ( 33 ) , NCI-H647 (pulmonary) ( 33 ) , NMuMG (epithelial) ( 146 ) , OCI/AML2 (myeloid) ( 173 ) , OPM-2 (plasma cell) ( 31 ) , ovary ( 20 ) , P31/FUJ (erythroid) ( 31 ) , PANC-1 (pancreatic) ( 102 , 153 ) , pancreas ( 155 ) , PC3 (prostate cell) ( 9 , 126 , 127 ) , PC9 (pulmonary) ( 33 ) , RAMOS (B lymphocyte) ( 191 ) , Rat1 (fibroblast) ( 179 ) , RAW 264 (macrophage) ( 166 ) , RL ('B lymphocyte, precursor') ( 31 ) , RPMI-8266 (plasma cell) ( 31 ) , S107 (B lymphocyte) ( 172 ) , SKBr3 (breast cell) ( 32 ) , ST88-14 (neuron) ( 115 ) , SU-DHL-6 (B lymphocyte) ( 31 ) , SUIT-2 (pancreatic) ( 40 ) , SW48 (intestinal) ( 157 ) , T lymphocyte ( 12 ) , T47D (breast cell) ( 76 ) , T98G (glial) ( 49 , 102 ) , thyroid ( 147 , 148 ) , TT (thyroid cell) ( 148 ) , U-251 MG (glial) ( 49 ) , U-937 (myeloid) ( 6 ) , U266 (plasma cell) ( 31 , 41 , 166 ) , UT-7 (myeloid) ( 176 ) , WI-38 (fibroblast) ( 3 ) , WM115 (melanocyte) ( 124 ) , WM239A (melanocyte) ( 14 ) , WM2664 (melanocyte) ( 102 )

Upstream Regulation
Regulatory protein:
CD5 (human) ( 43 ) , CDK5 (human) ( 148 ) , CDK5R1 (human) ( 148 ) , CNTF (human) ( 190 ) , DOR-1 (human) ( 161 ) , DYRK1A (rat) ( 171 ) , FZD2 (human) ( 18 ) , G-alpha 14 (human) ( 161 ) , G-alpha(s) (human) ( 149 ) , GRF-1 (human) ( 149 ) , HRas (human) ( 149 ) , IL6 (human) ( 142 ) , K12 (human) ( 26 ) , LIF (human) ( 142 ) , MEKK1 (human) ( 189 ) , MKK4 (human) ( 189 ) , mTOR (human) ( 120 , 139 ) , mTOR (mouse) ( 115 ) , MYDGF (human) ( 16 ) , NF1 (mouse) ( 115 ) , Nik (human) ( 144 ) , p63 (human) ( 135 ) , PIK3CD (human) ( 149 ) , PKCD (human) ( 150 ) , RAC1 (human) ( 115 , 149 , 189 ) , Raptor (mouse) ( 115 ) , Ret (human) ( 147 ) , RHOA (human) ( 149 ) , SMAD4 (human) ( 132 ) , Src (human) ( 149 ) , STAT1 (human) ( 4 ) , TRRAP (human) ( 117 ) , VAV1 (human) ( 189 )
Putative in vivo kinases:
CDK5 (human) ( 77 ) , GSK3A (human) ( 22 ) , GSK3B (human) ( 22 ) , JNK1 (human) ( 192 ) , JNK2 iso2 (human) ( 45 ) , NEK6 (human) ( 75 ) , P38A (human) ( 168 ) , PKCD (human) ( 150 ) , PKCE (human) ( 102 )
Kinases, in vitro:
CDK5 (human) ( 77 ) , GSK3B (human) ( 22 ) , IRAK1 (human) ( 159 ) , JNK1 (human) ( 170 , 192 ) , JNK2 iso2 (human) ( 45 ) , mTOR (mouse) ( 190 ) , NEK6 (human) ( 75 ) , PKCD (human) ( 150 ) , RSK2 (human) ( 170 )
Putative upstream phosphatases:
DUSP2 (human) ( 12 )
Phosphatases, in vitro:
DUSP2 (human) ( 12 )
Treatments:
8-Rp-cAMP ( 149 ) , adriamycin ( 9 ) , AG1478 ( 145 , 165 ) , AG490 ( 43 , 149 , 161 , 165 , 172 ) , alvocidib ( 140 ) , amino_acids ( 120 ) , anisomycin ( 192 ) , anti-IgM ( 191 ) , anti-IL-6 ( 187 ) , anti-VEGF ( 154 ) , apigenin ( 151 ) , arsenite ( 192 ) , AZ960 ( 40 ) , C5a ( 165 ) , calphostin_C ( 104 , 161 , 165 ) , cAMP_analog ( 149 ) , carbachol ( 149 ) , cholera_toxin ( 149 ) , cicaprost ( 152 ) , colforsin ( 149 ) , cryptotanshinone ( 127 ) , cucurbitacin-I ( 48 , 115 ) , DMSO ( 181 ) , DNP ( 25 ) , DPDPE ( 161 ) , EGCG ( 151 , 154 ) , EGF ( 4 , 22 , 76 , 149 , 162 , 192 , 194 ) , Epo ( 176 ) , ethanol ( 143 ) , FGF1 ( 104 , 195 ) , FGF7 ( 104 ) , G-CSF ( 185 ) , gambogic_acid ( 41 ) , GDNF ( 147 ) , genistein ( 150 ) , Go_6976 ( 150 ) , H-7 ( 166 , 168 , 181 , 185 , 190 ) , H-89 ( 9 , 149 ) , H2O2 ( 3 ) , HGF ( 164 , 184 ) , high_cell_density ( 146 , 163 ) , hypoxia ( 121 ) , ibuprofen ( 5 ) , ICI-118,551 ( 149 ) , IL-10 ( 174 ) , IL-12 ( 156 ) , IL-13 ( 39 , 150 , 168 ) , IL-2 ( 160 , 193 ) , IL-22 ( 174 ) , IL-3 ( 176 ) , IL-6 ( 2 , 49 , 77 , 128 , 139 , 140 , 150 , 164 , 172 , 175 , 180 , 181 , 183 , 187 , 189 ) , imatinib ( 147 ) , ischemia ( 20 ) , isoproterenol ( 149 ) , JAK3_inhibitor_I ( 149 , 161 , 165 ) , JAK_inhibitor_I ( 104 ) , KN-62 ( 161 , 165 ) , leptin ( 169 ) , LIGHT ( 144 ) , LPS ( 143 , 192 ) , luteolin ( 151 ) , LY294002 ( 115 , 149 , 165 , 184 ) , MGDF ( 188 ) , MK-591 ( 5 ) , okadaic_acid ( 192 ) , OPB-51602 ( 2 ) , PD98059 ( 16 , 43 , 132 , 166 , 176 , 181 , 182 , 184 , 185 , 189 , 191 , 192 , 193 , 195 ) , PDGF ( 182 ) , phorbol_ester ( 181 , 193 ) , PP1 ( 149 ) , PP2 ( 39 , 143 , 147 , 149 , 161 , 165 ) , PP3 ( 39 , 149 ) , PTX ( 149 , 161 , 165 ) , QLT0254 ( 155 ) , radicicol ( 165 ) , Raf1_kinase_inhibitor_I ( 149 , 152 , 161 , 165 ) , rapamycin ( 115 , 139 , 156 , 190 ) , regorafenib ( 1 ) , rottlerin ( 150 , 180 ) , ruxolitinib ( 1 ) , salicylate ( 166 ) , SB202190 ( 149 , 152 , 161 , 165 , 168 ) , SB202474 ( 152 ) , SB203580 ( 104 , 152 , 161 , 165 , 182 , 189 , 192 ) , SB600125 ( 143 ) , SCF ( 185 ) , seliciclib ( 148 ) , selumetinib ( 14 ) , serum_starvation ( 77 ) , silibinin ( 126 , 145 ) , silmitasertib ( 1 ) , siRNA ( 22 , 75 , 77 , 149 , 150 ) , SN-38 ( 77 ) , SP600125 ( 104 , 149 , 152 , 166 ) , stattic ( 16 ) , staurosporine ( 165 ) , SU11657 ( 154 ) , SU5402 ( 104 ) , SU6656 ( 39 , 104 ) , sunitinib ( 118 ) , tanshinone-1 ( 13 ) , TGF-beta ( 132 ) , tipifarnib ( 153 ) , TNF ( 192 ) , TRAP ( 22 ) , U0126 ( 4 , 76 , 104 , 124 , 147 , 149 , 152 , 161 , 165 , 172 , 176 ) , U73122 ( 149 , 161 , 165 ) , U73343 ( 149 ) , UCN-01 ( 157 ) , UV ( 26 , 170 , 192 ) , vemurafenib ( 14 ) , virus infection ( 26 , 131 ) , Wnt5a ( 18 ) , wortmannin ( 76 , 149 , 165 , 184 , 185 , 191 ) , XL413 ( 1 ) , Z-VAD-FMK ( 145 )

Downstream Regulation
Effects of modification on STAT3:
activity, induced ( 77 , 102 , 131 , 159 , 161 , 165 , 166 , 173 , 178 , 181 , 187 , 190 ) , activity, inhibited ( 192 ) , intracellular localization ( 3 , 45 , 77 , 128 , 169 ) , molecular association, regulation ( 9 , 77 , 102 , 150 , 175 , 183 ) , phosphorylation ( 22 )
Effects of modification on biological processes:
apoptosis, altered ( 48 ) , carcinogenesis, induced ( 26 , 102 ) , cell differentiation, altered ( 147 ) , cell growth, altered ( 45 , 128 , 147 , 148 ) , cell growth, induced ( 75 ) , cell motility, altered ( 102 ) , DNA repair, induced ( 77 ) , signaling pathway regulation ( 39 , 77 ) , transcription, altered ( 102 , 125 , 128 , 131 , 139 , 147 , 150 , 159 , 161 , 165 , 166 , 170 , 178 , 181 , 182 , 187 , 192 ) , transcription, induced ( 9 , 22 , 26 , 39 , 45 , 77 , 169 , 173 , 174 , 180 , 183 , 189 , 190 , 194 ) , transcription, inhibited ( 75 )
Induce interaction with:
DNA ( 9 , 77 , 102 , 150 ) , p300 (human) ( 183 )
Inhibit interaction with:
gp130 (human) ( 175 )

Disease / Diagnostics Relevance
Relevant diseases:
HNSCC ( 44 ) , clear cell kidney cancer ( 22 ) , pancreatic carcinoma ( 132 ) , prostate cancer ( 128 ) , medullary thyroid carcinoma ( 147 )

References 

1

Parri E, et al. (2020) Identification of novel regulators of STAT3 activity. PLoS One 15, e0230819
32231398   Curated Info

2

Genini D, et al. (2017) Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells. Proc Natl Acad Sci U S A 114, E4924-E4933
28584133   Curated Info

3

Meier JA, et al. (2017) Stress-induced dynamic regulation of mitochondrial STAT3 and its association with cyclophilin D reduce mitochondrial ROS production. Sci Signal 10
28351946   Curated Info

4

Malik A, Pal R, Gupta SK (2017) Interdependence of JAK-STAT and MAPK signaling pathways during EGF-mediated HTR-8/SVneo cell invasion. PLoS One 12, e0178269
28542650   Curated Info

5

Sarveswaran S, Varma N, Morisetty S, Ghosh J (2016) Inhibition of 5-lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of c-Jun N-terminal kinase. Oncotarget
27880719   Curated Info

6

Rutherford C, et al. (2016) Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling. Sci Signal 9, ra109
27919027   Curated Info

7

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

8

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

9

Niu J, et al. (2016) Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene 35, 1302-13
26028030   Curated Info

10

Saitoh M, et al. (2016) STAT3 integrates cooperative Ras and TGF-β signals that induce Snail expression. Oncogene 35, 1049-57
25961936   Curated Info

11

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

12

Lu D, et al. (2015) The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation. Nat Immunol 16, 1263-73
26479789   Curated Info

13

Wang Y, Li JX, Wang YQ, Miao ZH (2015) Tanshinone I inhibits tumor angiogenesis by reducing Stat3 phosphorylation at Tyr705 and hypoxia-induced HIF-1α accumulation in both endothelial and tumor cells. Oncotarget 6, 16031-42
26202747   Curated Info

14

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

15

Dasgupta M, Dermawan JK, Willard B, Stark GR (2015) STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. Proc Natl Acad Sci U S A 112, 3985-90
25767098   Curated Info

16

Korf-Klingebiel M, et al. (2015) Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. Nat Med 21, 140-9
25581518   Curated Info

17

Kühnemuth B, et al. (2015) CUX1 modulates polarization of tumor-associated macrophages by antagonizing NF-κB signaling. Oncogene 34, 177-87
24336331   Curated Info

18

Gujral TS, et al. (2014) A noncanonical frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell 159, 844-56
25417160   Curated Info

19

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

20

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

21

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

22

Waitkus MS, et al. (2014) Signal integration and gene induction by a functionally distinct STAT3 phosphoform. Mol Cell Biol 34, 1800-11
24615012   Curated Info

23

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

24

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

25

Tan G, et al. (2014) Dinitrosopiperazine-mediated phosphorylated-proteins are involved in nasopharyngeal carcinoma metastasis. Int J Mol Sci 15, 20054-71
25375189   Curated Info

26

King CA (2013) Kaposi's Sarcoma-Associated Herpesvirus Kaposin B Induces Unique Monophosphorylation of STAT3 at Serine 727 and MK2-Mediated Inactivation of the STAT3 Transcriptional Repressor TRIM28. J Virol 87, 8779-91
23740979   Curated Info

27

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

28

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

29

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

30

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

31

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

32

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

33

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

34

Gupta M, et al. (2012) Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 26, 1356-64
22116549   Curated Info

35

Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81
22497526   Curated Info

36

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

37

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

38

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

39

Bhattacharjee A, Pal S, Feldman GM, Cathcart MK (2011) Hck is a key regulator of gene expression in alternatively activated human monocytes. J Biol Chem 286, 36709-23
21878628   Curated Info

40

Corcoran RB, et al. (2011) STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71, 5020-9
21586612   Curated Info

41

Prasad S, Pandey MK, Yadav VR, Aggarwal BB (2011) Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis. Cancer Prev Res (Phila) 4, 1084-94
21490133   Curated Info

42

Guo A (2011) CST Curation Set: 12058; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

43

Garaud S, et al. (2011) CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol 186, 4835-44
21398617   Curated Info

44

Frederick MJ, et al. (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178, 548-71
21281788   Curated Info

45

Nitta RT, et al. (2011) The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis. Oncogene 30, 234-44
20871632   Curated Info

46

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

47

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

48

Ishdorj G, Johnston JB, Gibson SB (2010) Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Mol Cancer Ther 9, 3302-14
21159613   Curated Info

49

Liu Q, et al. (2010) IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol 100, 165-76
20361349   Curated Info

50

Zhou J (2010) CST Curation Set: 10708; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

51

Moritz A (2010) CST Curation Set: 10603; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

52

Moritz A (2010) CST Curation Set: 10611; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

53

Moritz A (2010) CST Curation Set: 10617; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

54

Moritz A (2010) CST Curation Set: 10606; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

55

Moritz A (2010) CST Curation Set: 10616; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

56

Moritz A (2010) CST Curation Set: 10602; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

57

Moritz A (2010) CST Curation Set: 10609; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

58

Moritz A (2010) CST Curation Set: 10604; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

59

Moritz A (2010) CST Curation Set: 10614; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

60

Moritz A (2010) CST Curation Set: 10615; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

61

Moritz A (2010) CST Curation Set: 10607; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

62

Moritz A (2010) CST Curation Set: 10610; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

63

Moritz A (2010) CST Curation Set: 10613; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

64

Moritz A (2010) CST Curation Set: 10605; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

65

Moritz A (2010) CST Curation Set: 10608; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

66

Moritz A (2010) CST Curation Set: 10612; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

67

Moritz A (2010) CST Curation Set: 10601; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

68

Moritz A (2010) CST Curation Set: 10599; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

69

Moritz A (2010) CST Curation Set: 10597; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

70

Moritz A (2010) CST Curation Set: 10594; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

71

Moritz A (2010) CST Curation Set: 10598; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

72

Moritz A (2010) CST Curation Set: 10600; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

73

Moritz A (2010) CST Curation Set: 10595; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

74

Moritz A (2010) CST Curation Set: 10596; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

75

Jeon YJ, et al. (2010) Role of NEK6 in tumor promoter-induced transformation in JB6 C141 mouse skin epidermal cells. J Biol Chem 285, 28126-33
20595392   Curated Info

76

Aksamitiene E, et al. (2010) PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal 22, 1369-78
20471474   Curated Info

77

Courapied S, et al. (2010) The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J Biol Chem 285, 26765-78
20516069   Curated Info

78

Moritz A (2010) CST Curation Set: 10233; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

79

Moritz A (2010) CST Curation Set: 10238; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

80

Moritz A (2010) CST Curation Set: 10235; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

81

Moritz A (2010) CST Curation Set: 10240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

82

Moritz A (2010) CST Curation Set: 10232; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

83

Moritz A (2010) CST Curation Set: 10237; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

84

Moritz A (2010) CST Curation Set: 10234; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

85

Moritz A (2010) CST Curation Set: 10241; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

86

Moritz A (2010) CST Curation Set: 10239; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

87

Moritz A (2010) CST Curation Set: 10242; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

88

Moritz A (2010) CST Curation Set: 10236; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

89

Moritz A (2010) CST Curation Set: 10231; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

90

Moritz A (2010) CST Curation Set: 10243; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

91

Moritz A (2010) CST Curation Set: 9985; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

92

Moritz A (2010) CST Curation Set: 9984; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

93

Moritz A (2010) CST Curation Set: 10021; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

94

Moritz A (2010) CST Curation Set: 10020; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

95

Moritz A (2010) CST Curation Set: 9983; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

96

Moritz A (2010) CST Curation Set: 9986; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

97

Moritz A (2010) CST Curation Set: 10022; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

98

Moritz A (2010) CST Curation Set: 9980; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

99

Moritz A (2010) CST Curation Set: 10023; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

100

Moritz A (2010) CST Curation Set: 9987; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

101

Possemato A (2010) CST Curation Set: 9793; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

102

Aziz MH, et al. (2010) Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene 29, 3100-9
20228845   Curated Info

103

Moritz A (2010) CST Curation Set: 9775; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

104

Dudka AA, Sweet SM, Heath JK (2010) Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification. Cancer Res 70, 3391-401
20388777   Curated Info

105

Possemato A (2010) CST Curation Set: 9441; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

106

Moritz A (2010) CST Curation Set: 9374; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

107

Moritz A (2010) CST Curation Set: 9373; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

108

Moritz A (2010) CST Curation Set: 9279; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

109

Moritz A (2010) CST Curation Set: 9234; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

110

Moritz A (2010) CST Curation Set: 9240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

111

Moritz A (2010) CST Curation Set: 9237; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

112

Moritz A (2010) CST Curation Set: 9243; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

113

Moritz A (2010) CST Curation Set: 8838; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

114

Moritz A (2010) CST Curation Set: 8837; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

115

Banerjee S, et al. (2010) The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res 70, 1356-66
20124472   Curated Info

116

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

117

Wurdak H, et al. (2010) An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 6, 37-47
20085741   Curated Info

118

Yang F, et al. (2010) Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 8, 35-45
20053726   Curated Info

119

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

120

Kim JH, Yoon MS, Chen J (2009) Signal transducer and activator of transcription 3 (STAT3) mediates amino acid inhibition of insulin signaling through serine 727 phosphorylation. J Biol Chem 284, 35425-32
19875458   Curated Info

121

Selvendiran K, et al. (2009) Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer 125, 2198-204
19623660   Curated Info

122

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

123

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

124

Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31
19362540   Curated Info

125

Saleh A, et al. (2009) Critical role for STAT3 in IL-17A-mediated CCL11 expression in human airway smooth muscle cells. J Immunol 182, 3357-65
19265112   Curated Info

126

Singh RP, et al. (2009) Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 15, 613-21
19147767   Curated Info

127

Shin DS, et al. (2009) Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 69, 193-202
19118003   Curated Info

128

Qin HR, et al. (2008) Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation. Cancer Res 68, 7736-41
18829527   Curated Info

129

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

130

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

131

Duechting A, et al. (2008) Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J Virol 82, 7942-52
18550668   Curated Info

132

Zhao S, et al. (2008) Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 68, 4221-8
18519681   Curated Info

133

Stokes M (2008) CST Curation Set: 4389; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

134

Sui S, et al. (2008) Phosphoproteome analysis of the human Chang liver cells using SCX and a complementary mass spectrometric strategy. Proteomics 8, 2024-34
18491316   Curated Info

135

Chu WK, Dai PM, Li HL, Chen JK (2008) Transcriptional activity of the DeltaNp63 promoter is regulated by STAT3. J Biol Chem 283, 7328-37
18198175   Curated Info

136

Stokes M (2008) CST Curation Set: 3881; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

137

Stokes M (2008) CST Curation Set: 3882; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

138

Stokes M (2008) CST Curation Set: 3883; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

139

Kim JH, et al. (2008) Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem 283, 708-15
17993646   Curated Info

140

Hou T, Ray S, Brasier AR (2007) The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression. J Biol Chem 282, 37091-102
17956865   Curated Info

141

Possemato A (2007) CST Curation Set: 3481; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

142

Ohbayashi N, et al. (2007) LIF- and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation. Biol Pharm Bull 30, 1860-4
17917251   Curated Info

143

Norkina O, et al. (2007) Acute alcohol activates STAT3, AP-1, and Sp-1 transcription factors via the family of Src kinases to promote IL-10 production in human monocytes. J Leukoc Biol 82, 752-62
17575268   Curated Info

144

Nadiminty N, et al. (2007) LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochem Biophys Res Commun 359, 379-84
17543278   Curated Info

145

Agarwal C, Tyagi A, Kaur M, Agarwal R (2007) Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 28, 1463-70
17341659   Curated Info

146

Su HW, et al. (2007) Cell confluence-induced activation of signal transducer and activator of transcription-3 (Stat3) triggers epithelial dome formation via augmentation of sodium hydrogen exchanger-3 (NHE3) expression. J Biol Chem 282, 9883-94
17276988   Curated Info

147

Plaza-Menacho I, et al. (2007) Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. J Biol Chem 282, 6415-24
17209045   Curated Info

148

Lin H, et al. (2007) Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. J Biol Chem 282, 2776-84
17145757   Curated Info

149

Liu AM, et al. (2006) Activation of STAT3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase. J Biol Chem 281, 35812-25
17008315   Curated Info

150

Bhattacharjee A, et al. (2006) Monocyte 15-lipoxygenase expression is regulated by a novel cytosolic signaling complex with protein kinase C delta and tyrosine-phosphorylated Stat3. J Immunol 177, 3771-81
16951338   Curated Info

151

Selvendiran K, et al. (2006) Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res 66, 4826-34
16651438   Curated Info

152

Lo RK, Wise H, Wong YH (2006) Prostacyclin receptor induces STAT1 and STAT3 phosphorylations in human erythroleukemia cells: a mechanism requiring PTX-insensitive G proteins, ERK and JNK. Cell Signal 18, 307-17
15979846   Curated Info

153

Venkatasubbarao K, Choudary A, Freeman JW (2005) Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res 65, 2861-71
15805288   Curated Info

154

Lee YK, et al. (2005) VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 19, 513-23
15703780   Curated Info

155

Yau CY, Wheeler JJ, Sutton KL, Hedley DW (2005) Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 65, 1497-504
15735038   Curated Info

156

Kusaba H, et al. (2005) Interleukin-12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR). J Biol Chem 280, 1037-43
15522880   Curated Info

157

Bhonde MR, et al. (2005) The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein. Oncogene 24, 148-56
15467762   Curated Info

158

Zhao H, et al. (2004) Region 752-761 of STAT3 is critical for SRC-1 recruitment and Ser727 phosphorylation. Biochem Biophys Res Commun 325, 541-8
15530426   Curated Info

159

Huang Y, Li T, Sane DC, Li L (2004) IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem 279, 51697-703
15465816   Curated Info

160

Chan SM, et al. (2004) Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med 10, 1390-6
15558056   Curated Info

161

Lo RK, Wong YH (2004) Signal transducer and activator of transcription 3 activation by the delta-opioid receptor via Galpha14 involves multiple intermediates. Mol Pharmacol 65, 1427-39
15155836   Curated Info

162

Shi CS, Kehrl JH (2004) Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation. J Biol Chem 279, 17224-31
14963038   Curated Info

163

Vultur A, et al. (2004) Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene 23, 2600-16
15007380   Curated Info

164

Schulze-Bergkamen H, et al. (2004) Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Hepatology 39, 645-54
14999683   Curated Info

165

Lo RK, Cheung H, Wong YH (2003) Constitutively active Galpha16 stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism. J Biol Chem 278, 52154-65
14551213   Curated Info

166

Liu H, et al. (2003) Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 102, 344-52
12637318   Curated Info

167

Krasilnikov M, Ivanov VN, Dong J, Ronai Z (2003) ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22, 4092-101
12821943   Curated Info

168

Xu B, et al. (2003) Interleukin-13 induction of 15-lipoxygenase gene expression requires p38 mitogen-activated protein kinase-mediated serine 727 phosphorylation of Stat1 and Stat3. Mol Cell Biol 23, 3918-28
12748293   Curated Info

169

Goren I, Pfeilschifter J, Frank S (2003) Determination of leptin signaling pathways in human and murine keratinocytes. Biochem Biophys Res Commun 303, 1080-5
12684046   Curated Info

170

Zhang Y, et al. (2003) Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3. J Biol Chem 278, 12650-9
12562765   Curated Info

171

Wiechmann S, et al. (2003) Unusual function of the activation loop in the protein kinase DYRK1A. Biochem Biophys Res Commun 302, 403-8
12604362   Curated Info

172

Kopantzev Y, Heller M, Swaminathan N, Rudikoff S (2002) IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells. Oncogene 21, 6791-800
12360405   Curated Info

173

Tarn C, Zou L, Hullinger RL, Andrisani OM (2002) Hepatitis B virus X protein activates the p38 mitogen-activated protein kinase pathway in dedifferentiated hepatocytes. J Virol 76, 9763-72
12208955   Curated Info

174

Lejeune D, et al. (2002) Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 277, 33676-82
12087100   Curated Info

175

Zhang T, Seow KT, Ong CT, Cao X (2002) Interdomain interaction of Stat3 regulates its Src homology 2 domain-mediated receptor binding activity. J Biol Chem 277, 17556-63
11872739   Curated Info

176

Haq R, et al. (2002) Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases. J Biol Chem 277, 17359-66
11875080   Curated Info

177

Zamo A, et al. (2002) Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21, 1038-47
11850821   Curated Info

178

Schuringa JJ, et al. (2001) MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 20, 5350-8
11536047   Curated Info

179

Faruqi TR, et al. (2001) Rac1 mediates STAT3 activation by autocrine IL-6. Proc Natl Acad Sci U S A 98, 9014-9
11470914   Curated Info

180

Schuringa JJ, Dekker LV, Vellenga E, Kruijer W (2001) Sequential activation of Rac-1, SEK-1/MKK-4, and protein kinase Cdelta is required for interleukin-6-induced STAT3 Ser-727 phosphorylation and transactivation. J Biol Chem 276, 27709-15
11335711   Curated Info

181

Abe K, et al. (2001) The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway. Oncogene 20, 3464-74
11429693   Curated Info

182

Deb A, et al. (2001) Protein kinase PKR is required for platelet-derived growth factor signaling of c-fos gene expression via Erks and Stat3. EMBO J 20, 2487-96
11350938   Curated Info

183

Schuringa JJ, Schepers H, Vellenga E, Kruijer W (2001) Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Lett 495, 71-6
11322950   Curated Info

184

Nakagami H, et al. (2001) Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 37, 581-6
11230338   Curated Info

185

Duarte RF, Frank DA (2000) SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways. Blood 96, 3422-30
11071637   Curated Info

186

Ahmed ST, Ivashkiv LB (2000) Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J Immunol 165, 5227-37
11046056   Curated Info

187

Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E (2000) Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 95, 3765-70
10845908   Curated Info

188

Challier C, et al. (2000) A new feature of Mpl receptor: ligand-induced transforming activity in FRE rat fibroblasts. Oncogene 19, 2033-42
10803464   Curated Info

189

Schuringa JJ, et al. (2000) Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochem J 347 Pt 1, 89-96
10727406   Curated Info

190

Yokogami K, Wakisaka S, Avruch J, Reeves SA (2000) Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 10, 47-50
10660304   Curated Info

191

Su L, Rickert RC, David M (1999) Rapid STAT phosphorylation via the B cell receptor. Modulatory role of CD19. J Biol Chem 274, 31770-4
10542198   Curated Info

192

Lim CP, Cao X (1999) Serine phosphorylation and negative regulation of Stat3 by JNK. J Biol Chem 274, 31055-61
10521505   Curated Info

193

Ng J, Cantrell D (1997) STAT3 is a serine kinase target in T lymphocytes. Interleukin 2 and T cell antigen receptor signals converge upon serine 727. J Biol Chem 272, 24542-9
9305919   Curated Info

194

Wen Z, Zhong Z, Darnell JE (1995) Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241-50
7543024   Curated Info

195

Udayakumar TS, Stratton MS, Nagle RB, Bowden GT Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3. Neoplasia 4, 60-7
11922392   Curated Info